Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

Delayed Quote. Delayed  - 09/27 05:35:13 pm
88.78 EUR   -0.47%
09/26 NEW CLINICAL GU : -- Iberogast™ recommended for the treatment ..
09/26DJLanxess Shares Rise on Acquisition of Chemtura
09/25 POLITICAL NOTES : Garamendi sends condolences
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Pfizer CEO: spin-off more likely for animal health

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/12/2012 | 03:47pm CEST

Pfizer Inc (>> Pfizer Inc.) is more likely to spin off its animal health unit than sell it outright, reflecting the expected investor appeal of such a large standalone business, its chief executive said on Monday.

Pfizer Inc (>> Pfizer Inc.) is more likely to spin off its animal health unit than sell it outright, reflecting the expected investor appeal of such a large standalone business, its chief executive said on Monday.

No final decision has been taken but Ian Read told Reuters there were clear attractions for shareholders in a tax-free spinoff of the operation, which is the biggest in the industry.

"I would probably handicap animal health as more likely to be a spin than a sale," the CEO of the world's biggest drugmaker said in an interview in London.

Read, who took over as Pfizer chief in December 2010 at a challenging time, is shrinking the group by divesting non-core businesses, including veterinary medicine and infant nutrition.

Pfizer is losing billions of dollars of revenue from cholesterol blockbuster Lipitor, which is now off patent in many markets, although Read said he hopes to carve out a new future for the medicine as an over-the-counter (OTC) product.

The nutrition business is widely expected to be sold outright for around $10 billion. Bidders were asked to submit offers last week, with Nestle SA (>> Nestle SA) and a partnership of Danone SA and Mead Johnson Nutrition Co (>> Mead Johnson Nutrition CO) seen as frontrunners.

The process for animal health, however, is less well advanced and the case for a sale less obvious. Pfizer faces a hefty tax bill if it sells outright and any buyer would also faces substantial antitrust hurdles.

"It's the largest animal health business and it would stand alone as an individual company. There's huge interest among investors to own a company like that," Read said.

"With nutritional there are lots of companies that are already in the nutritional business and have it as a major development area."

Speculation about a possible sale of animal health, which analysts believe could be worth $15-20 billion, was fuelled last week by reports that Novartis AG (>> Novartis AG) had made an approach that was rebuffed by Pfizer, while Bayer AG (>> Bayer AG) was also weighing a move.

The plans to dispose of both units, which Pfizer has said would be completed between July 2012 and July 2013, follows a far-reaching review and a decision to focus on core pharmaceutical operations.

The outcome of that review was to focus on five core areas of drug research, while maintaining a strong presence in generic and OTC medicines.

Read said Pfizer hoped to introduce a non-prescription form of Lipitor, but this would not happen in the short term. Pfizer is currently discussing the issue with the Food and Drug Administration, which is seeking public comment on the idea of making more medicines available OTC.

"We would like to sell it over the counter. We're in discussions and development with the FDA on that," Read said.

In the past, Pfizer has been a mergers and acquisitions machine, snapping up smaller rivals and partners to build out its portfolio.

It will continue to look for bolt-on acquisitions, including deals that could be "multiples" of 2010's $3.6 billion purchase of King Pharmaceuticals, Read said. But he did not see a need for another large-scale deal like the $67 billion purchase of Wyeth in 2009.

Asked about the possibility of buying out Bristol-Myers Squibb Co (>> Bristol Myers Squibb Co.), its partner on promising anti-clotting drug Eliquis, Read said: "I'm not sure that would create shareholder value. I think the partnership is working very well."

(Editing by Chris Wickham)

By Ben Hirschler and Kate Kelland

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
09/26 NEW CLINICAL GUIDELINES : -- Iberogast™ recommended for the treatment of f..
09/26DJLanxess Shares Rise on Acquisition of Chemtura
09/25 POLITICAL NOTES : Garamendi sends condolences
09/24 BAYER : buys Monsanto for $66 bln
09/23 BAYER : Flupyradifurone; Pesticide Tolerances
09/23 BAYER AT EUROTIER 2016 : -- Animal Health and Crop Protection from a single sour..
09/23 BAYER : New scholarships worth EUR 345,000 awarded by Bayer Foundation to promot..
09/22 BAYER : partners Bright Future Fund to improve access to innovative treatment fo..
09/22 MONSANTO : and industry execs defend wave of agribusiness mega-mergers
09/21 MONSANTO : and Bayer defend proposed $66 billion merger
More news
Sector news : Pharmaceuticals - NEC
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/27 Disney Prepping Twitter Bid
09/26 Monsanto/Bayer Merger Difficult, But Could Send MON Higher
09/22 Biontech Deal Sees Roche Bet On mRNA
09/22 Expect Glaxo To Increase Consumer Focus As Walmsley Takes Driving Seat
09/21 Bayer-Monsanto tie-up pilloried in Germany, U.S.
Advertisement
Financials (€)
Sales 2016 46 931 M
EBIT 2016 8 136 M
Net income 2016 4 791 M
Debt 2016 15 395 M
Yield 2016 3,01%
P/E ratio 2016 15,85
P/E ratio 2017 13,65
EV / Sales 2016 1,89x
EV / Sales 2017 1,75x
Capitalization 73 416 M
More Financials
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 109 €
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-23.33%82 947
JOHNSON & JOHNSON16.06%322 232
ROCHE HOLDING LTD.-12.41%215 081
NOVARTIS AG-10.14%211 231
PFIZER INC.4.80%204 049
MERCK & CO., INC.18.46%171 858
More Results